Single-drug parenteral estrogen treatment in prostatic cancer: a study of two maintenance-dose regimens

Prostate. 1989;14(2):183-8. doi: 10.1002/pros.2990140211.

Abstract

Treatment of 17 patients with prostatic cancer with 320 mg polyestradiol phosphate (PEP) as intramuscular injections every fourth week suppressed serum testosterone (T) values to orchidectomy levels within 1 month, and serum estradiol-17 beta (E2) rose to a mean level of 2,456 pmol/liter after 6 months. Following 6 months of treatment, the PEP dose was reduced to 80 mg/4 weeks in 9 and 160 mg/4 weeks in eight patients. Mean T levels, increased significantly after dose reduction in both groups and were above the upper orchidectomy limit at 1 month after dose reduction in the 80 mg group. Mean T levels, however, remained below this level at 5 months in the 160 mg group. Dose reduction caused a rise in gonadotropin levels in the 80 mg but not in the 160 mg group. While 320 mg/4 weeks may be a suitable initial dosage, doses less than or equal to 160 mg/4 weeks are insufficient as maintenance dosages if orchidectomy values of T are required.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Estradiol / administration & dosage
  • Estradiol / analogs & derivatives*
  • Estradiol / therapeutic use
  • Humans
  • Male
  • Orchiectomy
  • Prostatic Neoplasms / drug therapy*
  • Prostatic Neoplasms / surgery

Substances

  • Estradiol
  • polyestradiol phosphate